AGNPF
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.11 | $0 | -$465,935 |
| 2025 Q1 | -0.17 | $0 | -$356,495 |
| 2025 Q4 | -0.11 | $0 | -$488,728 |
| 2025 Q3 | -0.20 | $0 | -$174,524 |
| 2025 Q2 | -0.14 | $0 | -$249,421 |
| 2024 Q1 | -0.14 | $0 | -$244,039 |
| 2024 Q4 | -0.17 | $0 | -$663,774 |
| 2024 Q3 | 0.66 | $0 | -$2M |